Radiotherapy with rituximab may be better than radiotherapy
alone in first-line treatment of earlystage follicular
lymphoma: is it time to change the standard strategy?

J 2015

Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy?

JANÍKOVÁ, Andrea; Zbyněk BORTLÍČEK; Vit CAMPR; Natasa KOPALOVA; Katerina BENESOVA et al.

Základní údaje

Originální název

Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy?

Autoři

Vydání

Leukemia & Lymphoma, London, Informa Healthcare, 2015, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.093

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00084960

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Follicular lymphoma; rituximab; radiotherapy

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 3. 2016 11:49, Soňa Böhmová

Anotace

V originále

Early-stage follicular lymphoma (FL) has traditionally been treated with involved-fi eld radiotherapy (RT). Rituximab (R) is a low-toxic, effi cient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients with stage I – II indolent FL treated with RT (n=65) or RT + R (n=14) or R alone (n=14). Median follow-up was 5.0 years for patients with RT, 2.8 years for the RT + R subgroup and 2.5 years for patients treated with R. The complete response rate was 92%, 100% and 86% (not signifi cant) and the median PFS was 3.3 years, not reached and 4.9 years (p=0.035) for the RT, RT + R and R arms, with no impact on overall survival. R combined with RT seems to give better results in terms of global FL control, but longer follow-up and prospective comparison are needed to verify these results.

Citovat

JANÍKOVÁ, Andrea; Zbyněk BORTLÍČEK; Vit CAMPR; Natasa KOPALOVA; Katerina BENESOVA; David BELADA; Vit PROCHAZKA; Robert PYTLIK; Samuel VOKURKA; Jan PIRNOS; Juraj DURAS; Heidi MOCIKOVA; Jiří MAYER a Marek TRNENY. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy? Leukemia & Lymphoma. London: Informa Healthcare, 2015, roč. 56, č. 8, s. 2350-2356. ISSN 1042-8194. Dostupné z: https://doi.org/10.3109/10428194.2014.990010.

@article{1318860,
   author = {Janíková, Andrea and Bortlíček, Zbyněk and Campr, Vit and Kopalova, Natasa and Benesova, Katerina and Belada, David and Prochazka, Vit and Pytlik, Robert and Vokurka, Samuel and Pirnos, Jan and Duras, Juraj and Mocikova, Heidi and Mayer, Jiří and Trneny, Marek},
   article_location = {London},
   article_number = {8},
   doi = {https://doi.org/10.3109/10428194.2014.990010},
   keywords = {Follicular lymphoma; rituximab; radiotherapy},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & Lymphoma},
   title = {Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy?},
   volume = {56},
   year = {2015}
}

TY  - JOUR
ID  - 1318860
AU  - Janíková, Andrea - Bortlíček, Zbyněk - Campr, Vit - Kopalova, Natasa - Benesova, Katerina - Belada, David - Prochazka, Vit - Pytlik, Robert - Vokurka, Samuel - Pirnos, Jan - Duras, Juraj - Mocikova, Heidi - Mayer, Jiří - Trneny, Marek
PY  - 2015
TI  - Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy?
JF  - Leukemia & Lymphoma
VL  - 56
IS  - 8
SP  - 2350-2356
EP  - 2350-2356
PB  - Informa Healthcare
SN  - 10428194
KW  - Follicular lymphoma
KW  - rituximab
KW  - radiotherapy
N2  - Early-stage follicular lymphoma (FL) has traditionally been treated with involved-fi eld radiotherapy (RT). Rituximab (R) is a low-toxic, effi cient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients with stage I – II indolent FL treated with RT (n=65) or RT + R (n=14) or R alone (n=14). Median follow-up was 5.0 years for patients with RT, 2.8 years for the RT + R subgroup and 2.5 years for patients treated with R. The complete response rate was 92%, 100% and 86% (not signifi cant) and the median PFS was 3.3 years, not reached and 4.9 years (p=0.035) for the RT, RT + R and R arms, with no impact on overall survival. R combined with RT seems to give better results in terms of global FL control, but longer follow-up and prospective comparison are needed to verify these results.
ER  -

JANÍKOVÁ, Andrea; Zbyněk BORTLÍČEK; Vit CAMPR; Natasa KOPALOVA; Katerina BENESOVA; David BELADA; Vit PROCHAZKA; Robert PYTLIK; Samuel VOKURKA; Jan PIRNOS; Juraj DURAS; Heidi MOCIKOVA; Jiří MAYER a Marek TRNENY. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy? \textit{Leukemia \&{} Lymphoma}. London: Informa Healthcare, 2015, roč.~56, č.~8, s.~2350-2356. ISSN~1042-8194. Dostupné z: https://doi.org/10.3109/10428194.2014.990010.

Přehled o publikaci